HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

lenograstim

Subscribe to New Research on lenograstim

amino acid and carbohydrate sequence given in first source; RN given is for parent compound; Component 1 and Component 2 differ by absence or presence of Neu5Ac in 2-6 linkage to GalNAc side chain

Also Known As:

Amrad Brand of Lenograstim; Aventis Brand of Lenograstim; Chugai Brand of Lenograstim; Euprotin; Granocyte; Prasfarma Brand of Lenograstim; Rhône-Poulenc Rorer Brand of Lenograstim; lenograstim, Component 1; lenograstim, Component 2

Networked: 121 relevant articles (24 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kim, Shin: 3 articles (04/2008 - 04/2004)
2.	Suh, Cheolwon: 3 articles (04/2008 - 04/2004)
3.	Cheng, A C: 3 articles (01/2007 - 01/2003)
4.	Currie, B J: 3 articles (01/2007 - 01/2003)
5.	Stephens, D P: 3 articles (01/2007 - 01/2003)
6.	Oksuzoglu, Berna: 2 articles (01/2015 - 12/2014)
7.	Ehninger, Gerhard: 2 articles (08/2013 - 02/2011)
8.	Juan, O: 2 articles (05/2009 - 06/2001)
9.	Huh, Jooryung: 2 articles (04/2008 - 10/2005)
10.	Kim, Hyo-Jung: 2 articles (10/2005 - 04/2004)

Related Diseases

1.	Neutropenia 06/01/2001 - "The lower dose of lenograstim is cost-effective in neutropenia prophylaxis. " 07/01/2001 - "The incidence of febrile neutropenia in the first cycle was significantly lower in the lenograstim group than in the placebo group (9.2% vs 30.4%). " 07/01/2001 - "The median duration of neutropenia (neutrophils under 1,000/microl) was significantly shorter for the lenograstim group than the placebo group (2 days vs 9 days in the first cycle; 1 day vs 13 days in the second cycle). " 06/01/2001 - "Neutropenia grade III-IV was more common in patients receiving the low than in those receiving the standard dose of lenograstim (20% vs 12%, respectively), but the difference did not reach statistical significance (P=0.1). " 03/01/1999 - "and i.v. administered lenograstim to treat neutropenia, these results demonstrate that neutrophil responses are more sustained and prolonged with the s.c. "
2.	Infection 09/01/1997 - "Lenograstim treatment significantly (P = 0.012) reduced the incidence of treated infections and hospitalization for infection compared with the pre study period and significantly (P < 0.001) improved perceived health and disease-related symptoms. " 01/01/1994 - "These data demonstrate the possibility that such combination therapy may be applied to neutropenic patients with serious infections and that there is increased efficacy of antibiotic treatment when administered concurrently with lenograstim." 12/01/2004 - "The administration of lenograstim after HDT and ASCT significantly reduces the incidence of microbiologically defined infections until neutrophil recovery. " 12/01/2004 - "The incidence of infections until neutrophil recovery was significantly less in patients who received lenograstim after HDT and ASCT as compared to patients who received placebo (66 of 98 vs 86 of 94 patients, P<0.001). " 04/01/1997 - "Infections of > or = 2 severity were significantly less frequent (p = 0.001) among lenograstim recipients compared with placebo (25 vs 49). "
3.	Neoplasms (Cancer) 01/01/1994 - "The safety of lenograstim at doses up to 40 micrograms/kg/day has been demonstrated in Phase I studies involving 21 healthy volunteers and 37 cancer patients. " 12/01/2014 - "Classical DCF triplet with lenograstim showed a good clinical response with acceptable safety profile in the treatment of locally advanced gastric and gastroesophageal cancer with a significant R0 rate and manageable toxicity." 04/16/2011 - "In patients with cancer undergoing HSCT, lenograstim accelerated neutrophil recovery post-HSCT and shortened the duration of hospitalization, according to the results of randomized, multicentre trials. " 07/01/2001 - "The tumor response rate of the lenograstim group (57.8%) was higher than that of the placebo group (43.1%), but the difference was not statistically significant (chi2 = 2.634, df = 1, P = 0.105). " 05/01/1994 - "These findings confirm that lenograstim is a potent activator of neutrophil functions in non-neutropenic cancer patients and may be useful as an adjunct to conventional antimicrobial therapy."
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/01/2000 - "Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. " 09/01/2002 - "Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505." 04/01/2008 - "Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma." 10/01/2005 - "We conducted a prospective randomized comparative observation of the mobilization with a single dose (10 microg kg once a day) or split dose (5 microg kg twice a day) of lenograstim following chemotherapy in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma (NHL) patients. " 10/01/2005 - "Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma."
5.	Acquired Immunodeficiency Syndrome (AIDS) 11/01/2000 - "This phase IIa, randomised, single-blind, placebo-controlled study was conducted to determine the dose of recombinant human granulocyte colony-stimulating factor (lenograstim) suitable for use in AIDS patients. " 03/01/2000 - "Other studies show efficacy of lenograstim in patients with acute lymphoblastic leukaemia, aplastic anaemia, in children with severe chronic neutropenia and in the reversal of neutropenia related to antiviral therapy in patients with AIDS, although data are not extensive. " 11/01/2000 - "Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients." 05/01/1995 - "Preliminary data suggest that lenograstim is effective in increasing the neutrophil count in patients with severe chronic neutropenia (Kostmann's syndrome), as well as patients with AIDS or AIDS-related complex with zidovudine-induced neutropenia. "

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)
2.	Filgrastim (Neupogen)
3.	pegfilgrastim (Neulasta)
4.	severe chronic Neutropenia
5.	Ifosfamide
6.	Colony-Stimulating Factors (Colony Stimulating Factor)
7.	vinorelbine (Navelbine)
8.	docetaxel (Taxotere)
9.	Carboplatin (JM8)
10.	Mesna (Coenzyme M)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Stem Cell Transplantation
3.	Injections
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Hematopoietic Stem Cell Mobilization